Heron Therapeutics (FRA:AXD2) Buyback Yield %: 0.06 (As of Jul. 01, 2026)

What is Heron Therapeutics Buyback Yield %?

Heron Therapeutics FRA:AXD2 +0.42% 49 Buyback Yield % is 0.06 as of Jul. 01, 2026. GuruFocus rates FRA:AXD2 with a GF Score™ of 49/100 and a GF Value™ of €1.37 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 745 Biotechnology companies, Heron Therapeutics ranks better than 88.19% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Heron Therapeutics's current buyback yield was 0.06%.

Heron Therapeutics Buyback Yield % Related Terms

Heron Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Heron Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heron Therapeutics Buyback Yield % Chart

Heron Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Buyback Yield %

Get a 7-Day Free Trial

0.00

-26.13

-11.71

0.00

-7.60

Heron Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Buyback Yield %	Get a 7-Day Free Trial															-0.02	-0.02	-0.03	-7.48	0.03

FRA:AXD2 vs ENTX, OKYO, EDSA: Buyback Yield % Comparison

For the Biotechnology subindustry, Heron Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heron Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Buyback Yield % falls into.

Save Embed

49GF Score

Heron Therapeutics Inc FRA:AXD2

Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Heron Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Heron Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	15.634)	/	205.638888
	=	-7.60%

Heron Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (-0.044	+	0)		/	122.291536
	=	0.04%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →

What does a Buyback Yield % of 0.06 mean?

Heron Therapeutics (FRA:AXD2) has a Buyback Yield % of 0.06 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Heron Therapeutics and its competitors. According to the industry distribution chart, Heron Therapeutics ranks #88 out of 745 companies in the Biotechnology industry, placing it in the top 11.8%.

Is Heron Therapeutics' Buyback Yield % too high?

Heron Therapeutics' current Buyback Yield % is 0.06. Based on the distribution chart, Heron Therapeutics ranks #88 out of 745 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Heron Therapeutics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Heron Therapeutics' Buyback Yield % compare to ENTX and OKYO?

According to the Biotechnology industry distribution chart, Heron Therapeutics ranks #88 out of 745 companies for Buyback Yield %. This places Heron Therapeutics in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Buyback Yield % for a Biotechnology company?

A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Buyback Yield % mean?

A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Heron Therapeutics and its competitors. Heron Therapeutics's current Buyback Yield % is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Heron Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Heron Therapeutics (FRA:AXD2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.37, compared to a current price of €0.38 — trading 72.2% below its estimated fair value. The current Buyback Yield % is 0.06. Heron Therapeutics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Buyback Yield % calculated?

Buyback Yield % is calculated from a company's financial statements. For Heron Therapeutics (FRA:AXD2), the current Buyback Yield % is 0.06 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of €0.38 is trading 72.2% below its estimated GF Value™ of €1.37. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AXD2:

Buyback Yield %: 0.06
GF Value™: €1.37 vs. price of €0.38 (72.2% below fair value)
GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heron Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ENTX OKYO EDSA ACET RANI IBIO RNTX GOSS OSTX ELTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges HRTX:USA 0J4V:UK AXD2:Germany

Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518

Website https://www.herontx.com

Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

49GF Score

Get the complete analysis for FRA:AXD2

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38

Price

€1.37

GF Value

View FRA:AXD2 Analysis

See Buyback Yield % data for all stocks →